Evidence map›Paper›PMID 41469668›Full record

ArticleBMC medicine2025

Trop2 immuno-PET/CT imaging of prostate cancer: a proof-of-concept translational study.

Xingru Long, Shuxian An, Xuanbingning Nian, Dongsheng Xu, Weijun Wei, Xiaoli Lan, Liang Dong, Dawei Jiang

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06851663 (Trop2-targeted immunoPET Imaging of Solid Tumors), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06851663 phase2 / phase3recruitingnot on this map

Trop2-targeted immunoPET Imaging of Solid Tumors

TypeinterventionalSponsorRenJi HospitalRan2024 to 2027Enrolled400ConditionsSolid Tumor, Solid Carcinoma, Uroepithelial Carcinoma, Bladder CancerArms[68Ga]Ga-NOTA-T4, [68Ga]Ga-NOTA-RT4, [18F]F-RESCA-T4, [18F]F-RESCA-RT4
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xingru Long *Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Shuxian An *Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Rd, Shanghai, 200127, China.
Xuanbingning Nian *Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Dongsheng XuDepartment of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Rd, Shanghai, 200127, China.
Weijun WeiDepartment of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Rd, Shanghai, 200127, China.
Xiaoli LanDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. xiaoli_lan@hust.edu.cn.
Liang DongDepartment of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Rd, Shanghai, 200127, China. dongliang6672@renji.com.
Dawei JiangDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. daweijiang@hust.edu.cn.

Funding

Hubei Science and Technology Innovation Talent Program 2023DJC162Innovative Drug Research and Development-National Science and Technology Major Project 2025ZD1803403National Natural Science Foundation of China 22277031National Natural Science Foundation of China 82030052
6 · The paper itself

Abstract

backgroundProstate cancer (PCa) is the second leading cause of death in men and is highly prone to metastasis. This study aims to develop the novel immuno-PET/CT tracer targeting trophoblast cell surface antigen 2 (Trop2), a transmembrane protein overexpressed in aggressive prostate malignancies, and to investigate its diagnostic value in preclinical studies as well as its potential utility in detecting metastases in PCa patients.

methodsIntegrated analysis of TCGA, GEO, and HPA datasets revealed Trop2 overexpression in prostate adenocarcinoma. By labeling two Trop2-targeted nanobodies (His-tagged T4 and His-tag-free RT4) with

resultsBioinformatics analysis demonstrated Trop2 as a promising target for PCa diagnosis and treatment. In preclinical studies, both [

conclusionsThis work successfully establishes that Trop2 is a new biomarker for PCa, and Trop2 immuno-PET/CT imaging can detect PCa lymph node and osseous metastases. The superior tumor-to-background contrast and clinical safety of [

trial registrationNCT06851663. Retrospectively registered 02/24/2025.

Indexed as

Antigens, NeoplasmCell Adhesion MoleculesPositron Emission Tomography Computed TomographyProstatic NeoplasmsAgedAnimalsCell Line, TumorFluorine RadioisotopesGallium RadioisotopesHumansMaleMiceProof of Concept StudyRadiopharmaceuticalsAntigens, NeoplasmCell Adhesion MoleculesFluorine RadioisotopesGallium RadioisotopesRadiopharmaceuticalsTACSTD2 protein, humanImmuno-PET/CTNanobodyNuclear medicineProstate cancerTrop2

Identifiers

PMID41469668
PMCPMC12866200

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.